The purpose of this offering is to permit the assessment of risk factors associated with the metabolic syndrome, including cardiovascular risk and an identification of individuals at higher risk of developing diabetes mellitus.
Fasting required. Fasting is defined as no consumption of food or
beverage other than water for at least 9-12 hours prior to
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine
(NAC), when administered in therapeutic concentrations (for the
treatment of acetaminophen overdose), has been determined to
interfere with assays for Cholesterol, Uric Acid where "NAC
interference may lead to falsely low results." According to Beckman
Coulter, the NAC interference should be insignificant by 12 hours
after completion of the initial loading dose of an IV infusion
treatment regimen consisting of an initial loading dose of 150 mg/kg
administered over 1 hr, a second dose of 50 mg/kg administered over 4
hrs and a third dose of 100 mg/kg administered over 16 hrs.
Reported (Analytical Time)
The CPT codes provided are based on AMA guidelines and are for informational purposes only.
CPT coding is the sole responsibility of the billing party.
Please direct any questions regarding coding to the payer being billed.
Patient Preparation: If a Cholesterol measurement is to be performed along with Triglycerides, but not part of a Lipid Panel, then the patient should be fasting 9-12 hours prior to collection. If the Cholesterol is ordered as part of a Lipid Panel, then a fasting sample is not required. If the Triglyceride result is >400 mg/dL, Direct LDL will be performed at an additional charge (CPT code(s): 83721). Methodology: Spectrophotometry (SP); Enzymatic Reject Criteria: Gross hemolysis; anticoagulants other than heparin; moderate to gross icterus For Glucose: No additive red-top; sodium flouride/oxalate (grey-top) tube; heparinized plasma Transport Temperature: Refrigerated